The House Judiciary Committee voted before the summer congressional recess to approve and send to the House a bill observers said would overhaul the US patent system by weeding out bad patents and restraining excessive litigation over patents. The measure continues to be opposed by drug and biotech firms.
The bill reportedly would give parties more leeway to question patent validity and would limit damage awards in infringement cases.
“Past attempts at achieving comprehensive patent reform have met with stiff resistance,” said bill chief sponsor Rep. Howard Berman (D-CA).
From the September 01, 2007 Issue of MM+M - Medical Marketing and Media
